Patient Community Is FDA’s “Guiding Light” On Acceptable Drug Risks
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER’s Janet Woodcock says the community has the agency’s ear when it advocates new developments; cites need for an “adult conversation” in assessing when drugs should be made available to patients.
You may also be interested in...
FDA’s Patient-Focused Meetings: Round One Selections Include Diseases Broad And Rare
Breast and lung cancer, female sexual dysfunction and hemophilia are among 16 diseases that FDA will discuss with patients to get their perspective for drug development; additional diseases will be chosen in a future round.
ALS Patients Ask FDA To See Risk Their Way
An FDA panel got an earful on the review and regulation of drugs for amyotrophic lateral sclerosis Feb. 25 during a public hearing convened under the agency’s plan to involve patient networks in the regulatory process, particularly where it concerns lowering barriers to drug development for ALS.
ALS Drug Development Gets FDA Hearing, Could See Push For Surrogate Markers
The ALS Association says it worked with FDA to seek a public forum in which ALS patients can present their perspective on benefit/risk in development of drugs for their condition.